Work

Supplementary Figure 4 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure 4: Virus treatment increases CD8 activation in the periphery (D3) and combination therapy maintains the activation (D5)

DOI: 10.1158/2326-6066.22539604

Authors: Mohammed G. Ghonime, Kevin A. Cassady

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362618903

Cites:

Cited by:

Related to: 10